Thursday 19 September 2019 |
| 07:00-20:00 | | REGISTRATION
|
| 08:00-10:00 | | ESPE Obesity Working Group (OWG)
Chair(s): Tetyana Chaychenko (Kharkiv, Ukraine)
test
E2
|
| 08:00 | WG2.1 | Pathogenesis of Insulin Resistance |
| 08:24 | WG2.2 | EU vs. non-EU practices on Insulin Resistance assessment (ESPE ObWG project) |
| 08:48 | WG2.3 | Insulin function in obese children within the low and high ranges of impaired fasting glycemia |
| 09:12 | WG2.4 | Adolescent type 2 diabetes: Comparing prospective registries |
| 09:36 | WG2.5 | Youth onset T2D (2018 ISPAD Consensus Guidelines) |
| 08:00-10:00 | | ESPE Working Group on Disorders of Sex Development (DSD)
E1
Session head(s): Christa Flück (Bern, Switzerland)
|
| 08:00 | | Introduction |
| 08:05 | WG1.1 | Epigenetics and the androgen insensitivity syndrome |
| 08:25 | WG1.2 | Oligogenic origin of DSD |
| 08:45 | WG1.3 | Postpubertal outcome of boys born with hypospadias |
| 09:05 | WG1.4 | Shared or Shaped Decision-Making in DSD |
| 09:25 | WG1.5 | i-dsd/i-cah |
| 09:35 | WG1.6 | Endo-ERN |
| 09:45 | | Discussion with attendees |
| 09:55 | | Conclusion |
| 08:00-10:00 | | ESPE Working Group on Bone and Growth Plate (BGP)
F1
Session head(s): Ciara McDonnell (Dublin, Ireland)
|
| 08:00 | WG3.1 | Lethal pyridoxin-independent encephalopathy in a case of perinatal hypophosphatasia |
| 08:15 | WG3.2 | Congenital talipes equinovarus and bowing of femur due to homozygous TRPV6 mutation |
| 08:30 | WG3.3 | Mechanisms of vascular calcification and potential treatment implications |
| 09:05 | WG3.4 | Update on BOND |
| 09:25 | WG3.5 | New insights in growth plate fusion |
| 08:00-10:00 | | ESPE Working Group on Diabetes Technology (DT)
F2
Session head(s): Moshe Philip (Petah Tikva, Israel)
|
| | Introduction |
| 08:05 | WG4.1 | Impact of hypoglycemia on cognitive function |
| 08:25 | WG4.2 | Impact of hyperglycemia on cognitive function |
| 08:45 | WG4.3 | Type 2 diabetes and the brain |
| 09:05 | WG4.4 | Fear of hyperglycemia |
| 09:20 | WG4.5 | Time in Range (TIR) - Highlights from the consensus meeting February 2019 |
| 09:40 | WG4.6 | How technology helps to improve TIR (open and closed loop) |
| 08:00-10:00 | | ESPE Working Group on Paediatric and Adolescent Gynaecology (PAG)
HALL B
Session head(s): Anne-Simone Parent (Liège, Belgium) & Ken Ong (Cambridge, United Kingdom)
|
| 08:00 | WG5.1 | Early Origins of PCOS |
| 08:23 | WG5.2 | Diagnosis & pharmacological intervention in PCOS |
| 08:46 | WG5.3 | Lifestyle intervention in PCOS |
| 09:09 | WG5.4 | Androgen Excess in female athletes |
| 09:32 | WG5.5 | Contraception in adolescence |
| 08:00-10:00 | | ESPE Working Group on Gender Dysphoria (GD)
HALL C
Session head(s): Gary Butler (London, United Kingdom)
|
| 08:00 | WG6.1 | Assessing competence to consent to physical treatment in transgender adolescents |
| 08:30 | WG6.2 | Surgical options for the transfemale |
| 09:00 | WG6.3 | Surgical options for the transmale |
| 09:30 | WG6.4 | Annual General Meeting |
| 08:00-10:00 | | ESPE Working Group on Turner Syndrome (TS)
HALL A
Session head(s): Michael Ranke (Tuebingen, Germany), Aneta Gawlik (Katowice, Poland), Malcolm Donaldson (Glasgow, United Kingdom) & Christina Kanaka-Gantenbein (Athens, Greece)
|
| 08:00 | | Introduction |
| 08:05 | WG7.1 | Oral versus transdermal induction of puberty - The Turner Working Group of ESPE proposal |
| 08:15 | WG7.2 | Theoretical and practical implications of transdermal approach to pubertal induction |
| 08:30 | | Discussion |
| 08:40 | WG7.3 | Endocrine management of Turner Syndrome in adolescents and early adulthood |
| 09:05 | WG7.4 | Fertility preservation- technical and ethical aspects |
| 09:30 | WG7.5 | Cardiac morbidity and mortality during pregnancy in TS |
| 09:55 | | Closing remarks |
| 10:00-10:30 | | REFRESHMENT BREAK, POSTERS & EXHIBTION
Exhibition Area
|
| 10:30-10:45 | | OPENING CEREMONY
HALL A
|
| 10:45-11:15 | | PLENARY 1 - RANKL and RANK: Bone and Beyond
Chair(s): Gabriele Häusler (Vienna, Austria) & Agnès Linglart (Paris, France)
HALL A
|
| PL1 | RANKL and RANK: Bone and beyond |
| 11:15-11:45 | | ESPE AWARDS - Henning Andersen Prizes
HALL A
Session head(s): Mehul Dattani (London, United Kingdom)
|
| 12:00-13:30 | | SYMPOSIUM 1
Chair(s): Martin Wabitsch (Ulm, Germany) & Jan Lebl (Prague, Czech Republic)
Novel advances in Diabetes and Obesity
HALL B
|
| S1.1 | Off the weight curve – dynamics of childhood obesity |
| S1.2 | The gut microbiome and Obesity |
| S1.3 | New developments for treatments in monogenic disorders focusing on setmelanotide trials |
| 12:00-13:30 | | SYMPOSIUM 2
Chair(s): Wolfgang Högler (Linz, Austria) & Dov Tiosano (Haifa, Israel)
What’s new in bone and growth plate research.
E1
|
| S2.1 | Longitudinal bone growth: fundamental mechanisms to clinical applications |
| S2.2 | Anabolic therapies for osteoporosis in childhood |
| S2.3 | Steroid-Associated Osteoporosis in the Pediatric Population |
| 12:00-13:30 | | SYMPOSIUM 3
Chair(s): Olaf Hiort (Lubeck, Germany) & Laura Audi (Barcelona, Spain)
Novel insights in our understanding of Disorders of Sex Development: From Genes to Clinical Outcomes
HALL A
|
| S3.1 | Genetics of DSD – do we understand it? |
| S3.2 | Outcomes in DSD – insight from the DSD life study |
| S3.3 | Novel insights into sex determination |
| 12:00-13:30 | | SYMPOSIUM 4
Chair(s): Zdeněk Šumník (Prague, Czech Republic) & Thomas Danne (Hanover, Germany)
ISPAD/ESPE Symposium - Complications of Type 1 Diabetes
HALL C
|
| S4.1 | Hypoglycemia in children with T1D: Past, Present, and Future |
| S4.2 | Novel advances in diabetic retinopathy screening and management |
| S4.3 | Prediction of renal and cardiovascular complications |
| 12:00-13:30 | | ESPE ACTIVITIES
E2
|
| ACT1 | eLearning RLC portal |
| ACT2 | Science Committee activities |
| ACT3 | Education and training activities |
| 13:30-14:45 | | LUNCH, POSTERS & EXHIBITION
Exhibition Area
|
| 13:45-14:45 | | Industry Sponsored Satellite Symposia
|
| 14:45-15:45 | | MEET THE EXPERT 1.1
Holistic approach to the individual with DSD
HALL B
|
| MTE1.1 | Holistic approach to the individual with DSD |
| 14:45-15:45 | | MEET THE EXPERT 2.1
The interpretation of abnormal thyroid function tests in children and adolescents
HALL C
|
| MTE2.1 | The interpretation of abnormal thyroid function tests in children and adolescents |
| 14:45-16:15 | | HOW DO I...
Chair(s): John Gregory (Cardiff, United Kingdom)
HOW DO I... SESSION 1
HALL A
|
| 14:45 | HDI1.1 | How Do I... Manage subclinical hypothyroidism |
| 15:15 | HDI1.2 | How Do I... Manage a patient with Prader Willi and GH at transition - do they benefit as adults? |
| 15:45 | HDI1.3 | How do I... Manage a child with insulin resistance |
| 14:45-16:15 | | FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 2 - Bone, growth plate and mineral metabolism Session 1
Chair(s): Elisabeth Steichen-Gersdorf (Innsbruck, Austria) & Dirk Schnabel (Berlin, Germany)
E2
|
| 14:45 | RFC2.1 | Burosumab resulted in better clinical outcomes than continuation with conventional therapy in both younger (1-4 years-old) and older (5-12 years-old) children with X-linked hypophosphatemia |
| 14:50 | RFC2.2 | Does the treatment with recombinant human growth hormone improve final height in patients affected by X-linked hypophosphatemia? |
| 14:55 | RFC2.3 | Growth hormone effects on metacarpal bone geometry and bone age in growth hormone-deficient children |
| 15:00 | RFC2.4 | Bone mass and fracture prevalence in childhood brain cancer survivors 2, 5 or 7 years after off therapy |
| 15:05 | RFC2.5 | Long term effects of treatment with oxandrolone (Ox) in addition to growth hormone (GH) in girls with Turner syndrome (TS) on bone mineral density in adulthood |
| 15:10 | RFC2.6 | Impact of pubertal suppression on body composition and bone mineral density in adolescents with gender dysphoria |
| 15:15 | FC2.1 | Continued improvement in clinical outcomes with burosumab, a fully human anti-FGF23 monoclonal antibody: results from a 3-year, phase 2, clinical trial in children with X-linked hypophosphatemia (XLH) |
| 15:25 | FC2.2 | Benefits of long-term burosumab persist in 11 girls with X-linked hypophosphatemia (XLH) who transitioned into adolescence during the phase 2 CL201 trial |
| 15:35 | FC2.3 | Higher dose of burosumab is needed for treatment of children with severe forms of X linked hypophosphatemia |
| 15:45 | FC2.4 | New imaging approaches to the quantification of musculoskeletal alterations in X-linked hypophosphatemic rickets (XLH) |
| 15:55 | FC2.5 | Age and gender-specific reference data for high-resolution magnetic resonance based musculoskeletal parameters in healthy children and young people |
| 16:05 | FC2.6 | Validation of a new version of BoneXpert bone age in children with congenital adrenal hyperplasia (CAH), precocious puberty (PP), growth hormone deficiency (GHD), Turner syndrome (TS), and other short stature diagnoses |
| 14:45-16:15 | | FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 3 - Multi-system endocrine disorders
Chair(s): Leena Patel (Manchester, United Kingdom) & Senthil Senniappan (LIverpool, UK)
F1
|
| 14:45 | RFC3.1 | European Registries For Rare Endocrine Conditions (EuRRECa): results from the pilot phase of The Platform For e-Reporting Of Rare Endocrine Conditions (e-REC) |
| 14:50 | RFC3.2 | Factors affecting loss to follow-up for patients with chronic endocrine conditions during the pediatric period: a cohort study at a reference center for rare diseases |
| 14:55 | RFC3.3 | The founder homozygous NR5A1 gene mutation p.R103Q causes asplenia and severe XY-DSD and XX-DSD in a Palestinian cohort |
| 15:00 | RFC3.4 | Peripheral glucocorticoid metabolism may reflect resolution of inflammation in Kawasaki disease |
| 15:05 | RFC3.5 | Evaluation of endothelial function in childhood standard risk acute lymphoblastic leukemia survivors: role of subclinical markers and identification of preventable factors |
| 15:10 | RFC3.6 | Prevalence of endocrine complications in Duchenne muscular dystrophy |
| 15:15 | FC3.1 | Germline-derived gain-of-function variants of Gsα-coding GNAS gene identified in nephrogenic syndrome of inappropriate antidiuresis: the first report |
| 15:25 | FC3.2 | CFTR loss-of-function has effects on microRNAs (miRNAs) that regulate genes involved in growth, glucose metabolism and in fertility in in vitro models of cystic fibrosis |
| 15:35 | FC3.3 | Variability in drug metabolizing cytochrome P450 activities caused by human genetic variations in NADPH cytochrome P450 oxidoreductase (POR) |
| 15:45 | FC3.4 | Droplet digital PCR is a useful method for detection of mosaic mutations in patients with McCune–Albright syndrome |
| 15:55 | FC3.5 | Evaluation of endocrine late effects in survivors of childhood allogeneic hematopoietic stem cell transplantation in Australia database from 1985 to 2011 |
| 16:05 | FC3.6 | Severe infections contribute to increased risk of early death in patients with apeced |
| 14:45-16:15 | | FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 1 - Diabetes and Insulin Session 1
Chair(s): Sabine Hofer (Innsbruck, Austria) & Reinhard Holl (Ulm, Germany)
E1
|
| 14:45 | RFC1.1 | Low prevalence of maternal microchimerism in Japanese children with type 1 diabetes |
| 14:50 | RFC1.2 | Gabra5 contributes to sexual dimorphism in POMC neural activity and glucose metabolism |
| 14:55 | RFC1.3 | The association between IGF-1 levels and nonalcoholic fatty liver disease (NAFLD) in adolescents with type 2 diabetes |
| 15:00 | RFC1.4 | Estimation of MODY frequency and prevalent subtypes in pediatric patients by targeted NGS |
| 15:05 | RFC1.5 | Decreased circulating levels of MOTS-c in individuals with newly diagnosed type 1 diabetes children |
| 15:10 | RFC1.6 | An oral trace element supplementation has a potential beneficial effect on glucose homeostasis in transfused patients with β-thalassemia major complicated with diabetes mellitus |
| 15:15 | FC1.1 | Insulin resistance leads to mitochondrial dysfunction in hepatocyte |
| 15:25 | FC1.2 | Three new genes (PTPRD, SYT9, and WSF1) related to Korean maturity-onset diabetes in the young (MODY) children decrease insulin synthesis and secretion in human pancreatic beta cells |
| 15:35 | FC1.3 | Next generation sequencing in Greek MODY patients increases diagnostic accuracy and reveals a high percentage of MODY12 cases |
| 15:45 | FC1.4 | ABSTRACT WITHDRAWN |
| 15:55 | FC1.5 | FADES: A birth cohort to understand the mechanisms underlying accelerated onset of autoimmunity in children with Down’s syndrome |
| 16:05 | FC1.6 | A novel biochemical marker, fatty acid-binding protein 4, in diabetic ketoacidosis in children |
| 16:15-16:30 | | REFRESHMENT BREAK, POSTERS AND EXHIBITION
Exhibition Area
|
| 16:30-17:00 | | PLENARY 2
Light, Body Clocks and Sleep: Biology to New Therapeutics
HALL A
Session head(s): Peter Clayton (Manchester, United Kingdom) & Annette Grüters (Heidelberg, Germany)
|
| PL2 | Light, Body Clocks and Sleep: Biology to New Therapeutics |
| 17:00-18:00 | | MEET THE EXPERT 3.1
Clinical Practice Guidelines for the Care of Girls and Women with Turner Syndrome: Proceedings from the 2016 Cincinnati International Turner Syndrome Meeting
HALL B
|
| MTE3.1 | Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting |
| 17:00-18:00 | | MEET THE EXPERT 4.1
Klinefelter syndrome - when should testosterone be started
HALL C
|
| MTE4.1 | Klinefelter syndrome - when should testosterone be started |
| 17:00-18:00 | | YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 1
HALL A
Session head(s): Wieland Kiess (Liepzig, Germany)
|
| 17:00 | YB1.1 | Adrenals |
| 17:12 | YB1.2 | Antenatal and Neonatal Endocrinology |
| 17:24 | YB1.3 | Bone, Growth Plate and Mineral Metabolism |
| 17:36 | YB1.4 | Type 2 Diabetes, Metabolic Syndrome and Lipids |
| 17:48 | YB1.5 | Editor's Choice |
| 17:00-18:30 | | FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 5 - Thyroid
Chair(s): Malgorzata Wasniewska (Messina, Italy) & A. S. Paul Van-Trotsenburg (Amsterdam, The Netherlands)
E2
|
| 17:00 | RFC5.1 | Hurthle cell carcinoma in childhood retrospective analysis of a large series |
| 17:05 | RFC5.2 | Ultrasound features of multinodular goiter in DICER1 syndrome |
| 17:10 | RFC5.3 | Experience of thyroid surgery in children with intraoperative neuromonitoring |
| 17:15 | RFC5.4 | Thyroid dysfunction in patients following thymus transplantation in a tertiary centre: a 10-year experience |
| 17:20 | RFC5.5 | A novel mutation in the thyroglobulin gene leading to neonatal goiter and congenital hypothyroidism in an Eritrean infant |
| 17:25 | RFC5.6 | Complex single nucleotide polymorphisms in SEPINA 7 lead to TBG deficiency |
| 17:30 | FC5.1 | Randomised trial of block and replace versus dose titration antithyroid drug treatment in children and adolescents with thyrotoxicosis |
| 17:40 | FC5.2 | Lower proportion of CD19+IL-10+ and CD19+CD24hiCD27+ IL-10+, but not CD1d+CD5+CD19+CD24+CD27+ IL-10+ B cells in children with autoimmune thyroid diseases |
| 17:50 | FC5.3 | Predominant DICER1 mutations in pediatric follicular thyroid carcinomas |
| 18:00 | FC5.4 | Thyroid dysgenesis: exome-wide analysis identifies rare variants in genes involved in thyroid development and cancer |
| 18:10 | FC5.5 | Identification of TRPC4AP as a novel candidate gene causing thyroid dysgenesis |
| 18:20 | FC5.6 | Homozygous loss-of-function mutation in the SLC26A7 gene coding a novel iodide transporter causes goitrous congenital hypothyroidism |
| 17:00-18:30 | | FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 4 - Fat, metabolism and obesity
Chair(s): Julie Chowen (Madrid, Spain) & Moshe Philip (Petah Tikva, Israel)
E1
|
| 17:00 | RFC4.1 | Expression of miRNAs in circulating exosomes derived from patients with NAFLD |
| 17:05 | RFC4.2 | Circulating exosomal miRNAs in children’s nonalcoholic steatohepatitis and the correlation with serum transaminase and uric acid |
| 17:10 | RFC4.3 | Dysregulated gene expression profile in visceral adipose tissue of juvenile Wistar rats with catch-up growth: association with fat expansion and metabolic parameters |
| 17:15 | RFC4.4 | The novel phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib effectively inhibits growth of PTEN haploinsufficient lipoma cells |
| 17:20 | RFC4.5 | GDF5 increased white adipose tissue thermogenesis through p38 MAPK signaling pathway in fatty acid-binding protein 4-GDF5 transgenic mice |
| 17:25 | RFC4.6 | Appetite suppressing effects of glucoregulatory peptides devoid of nausea |
| 17:30 | FC4.1 | Involvement of visfatin in adipose tissue fibrosis through modulation of extracellular matrix proteins |
| 17:40 | FC4.2 | Characterization of the adipose progenitor cell marker MSCA1 in normal weight and obese children |
| 17:50 | FC4.3 | Circulating growth-and-differentiation factor-15 in early life: relation to prenatal and postnatal size |
| 18:00 | FC4.4 | The rs72613567:TA variant in the hydroxysteroid 17-beta dehydrogenase 13 gene reduces liver damage in obese children |
| 18:10 | FC4.5 | Leptin gene methylation status in Egyptian infants |
| 18:30 | FC4.6 | Brain satiety responses to a meal in children before and after weight management intervention |
| 18:30-20:00 | | Industry-Sponsored Satellite Symposia
|
| 20:00-21:30 | | Informal ESPE Networking Event
|
Friday 20 September 2019 |
| 07:30-19:30 | | REGISTRATION
|
| 08:30-09:30 | | MEET THE EXPERT 5.1
Managing endocrinopathies in McCune-Albright Syndrome
E1
|
| MTE5.1 | Managing endocrinopathies in McCune-Albright Syndrome |
| 08:30-09:30 | | MEET THE EXPERT 6.1
Management of Diabetic Ketoacidosis
HALL B
|
| MTE6.1 | Management of Diabetic Ketoacidosis |
| 08:30-09:30 | | MEET THE EXPERT 7.1
Management of Graves disease
E2
|
| MTE7.1 | Management of Graves disease |
| 08:30-09:30 | | MEET THE EXPERT 8.1
Management of neonatal hypoglycaemia
HALL C
|
| MTE8.1 | Management of neonatal hypoglycaemia |
| 08:30-09:30 | | MEET THE EXPERT 1.2
Holistic approach to the individual with DSD
F1
|
| MTE1.2 | Holistic approach to the individual with DSD |
| 08:30-09:30 | | YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 2
Chair(s): Feyza Darendeliler (Istanbul, Turkey)
HALL A
|
| 08:30 | YB2.1 | DSD and gender dysphoria |
| 08:42 | YB2.2 | Growth and Growth Factors |
| 08:54 | YB2.3 | Obesity and Weight Regulation |
| 09:06 | YB2.4 | Oncology and Chronic Disease |
| 09:18 | YB2.5 | Global Health for the Paediatric Endocrinologist |
| 09:30-11:00 | | FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 6 - Bone, growth plate and mineral metabolism Session 2
Chair(s): Poonam Dhamaraj (Liverpool, United Kingdom) & Ola Nilsson (Stockholm, Sweden)
HALL B
|
| 09:30 | RFC6.1 | EFTUD2 gene deficiency disturbs maturation of osteoblast and inhibits chondrocyte differentiation via activated p53 signaling |
| 09:35 | RFC6.2 | High levels of LIGHT/TNFSF14 in Prader–Willi syndrome |
| 09:40 | RFC6.3 | Increased burden of common risk alleles in children with a significant fracture history |
| 09:45 | RFC6.4 | Targeted molecular genetic diagnosis by next generation sequence analysis method and investigation of responsible candidate genes in patients with osteogenesis imperfecta |
| 09:50 | RFC6.5 | Evaluating genotype–phenotype correlation using an in vitro mutagenesis model in bi-allelic mutations resulting in extreme hypophosphatasia clinical phenotypes |
| 09:55 | RFC6.6 | Genetic aetiology predicts growth hormone (GH) treatment outcomes in children born small-for-gestational-age with persistent short stature (SGA-SS). Lessons from a single-centre cohort |
| 10:00 | FC6.1 | Bone tissue characterization of a mouse model of atypical type VI osteogenesis imperfecta reveals hypermineralization of the bone matrix, elevated osteocyte lacunar density and altered vascularity |
| 10:10 | FC6.2 | Zone wise cell separation methods comparison, based on relative expression of specific growth plate markers in a pig model |
| 10:20 | FC6.3 | Decreased trabecular bone mineral density and muscle area at the forearm despite improvement in glycaemic control over 3 years after simultaneous pancreas kidney transplantation |
| 10:30 | FC6.4 | Metabolically unhealthy obese children and adolescents have higher bone mineral density than normal weighted controls but lower than metabolically healthy obeses: no effect of FGF21 levels |
| 10:40 | FC6.5 | No change in bone density during 6 months off GH in adolescents with severe GHD at near-adult height |
| 10:50 | FC6.6 | Craniosynostosis in inactivating PTH/PTHrP signaling disorder 2: a non-classical feature to consider |
| 09:30-11:00 | | FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 7 - Diabetes and Insulin Session 2
Chair(s): Birgit Rami-Merhar (Vienna, Austria) & Ram Weiss (Jerusalem, Israel)
HALL C
|
| 09:30 | RFC7.1 | Accuracy of glucose sensor estimate of HbA1c in children with type 1 diabetes |
| 09:35 | RFC7.2 | β-cell function and glucose effectiveness in the development of impaired fasting glucose in obese European children and adolescents |
| 09:40 | RFC7.3 | Osteopontin as an early urinary marker of diabetic nephropathy in adolescents with type 1 diabetes mellitus |
| 09:45 | RFC7.4 | Handgrip strength correlates with insulin resistance and the metabolic syndrome in children and adolescents: analysis of the Korean National Health and Nutrition Examination Survey 2014-2016 |
| 09:50 | RFC7.5 | Dual diagnosis of type 1 diabetes and ADHD |
| 09:55 | RFC7.6 | Health-related quality of life and diabetes control in immigrant and Italian children and adolescents with type 1 diabetes and in their parents |
| 10:00 | FC7.1 | Deployment of a predictive model based on CpG methylation haplotypes analysis on the insulin gene promoter, in a cohort of children and adolescents with type 1 diabetes |
| 10:10 | FC7.2 | Copeptin kinetics and its relationship to osmolality during rehydration for diabetic ketoacidosis in children: an observational study |
| 10:20 | FC7.3 | ABSTRACT WITHDRAWN |
| 10:30 | FC7.4 | Metabolic syndrome features in pre-pubertal children born after maternal pre-eclampsia |
| 10:40 | FC7.5 | Is the 1-hour post-load glucose level by 75g oral glucose tolerance test a new risk factor in predicting atherosclerosis? |
| 10:50 | FC7.6 | 2017 American Academy of Pediatrics Clinical Practice Guideline: impact on prevalence of arterial hypertension in children and adolescents with type 1 diabetes mellitus |
| 09:30-11:00 | | FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 8 - Pituitary, neuroendocrinology and puberty Session 1
Chair(s): Evelien Gevers (London, United Kingdom) & Juliane Léger (Paris, France)
E1
|
| 09:30 | RFC8.1 | Trade-off between olfactory bulb and eyeball volume in precocious puberty |
| 09:35 | RFC8.2 | Investigation of imprinting alterations in MKRN3 and DLK1 in a cohort of girls with central precocious puberty through specific DNA methylation analysis |
| 09:40 | RFC8.3 | Central precocious puberty caused by novel mutations in the promoter and 5′-UTR region of the imprinted MKRN3 gene |
| 09:45 | RFC8.4 | Evaluation of puberty in patients with Noonan syndrome and mutations in the RAS/MAPK genes |
| 09:50 | RFC8.5 | CHD7 mutations in patients with anosmic or normosmic idiopathic hypogonadotropic hypogonadism |
| 09:55 | RFC8.6 | Growth, pubertal course and long-term outcome of 46,XY boys born with atypical genitalia and low birthweight |
| 10:00 | FC8.1 | Hypothalamic AgRP neurons drive endurance in food-restricted mice |
| 10:10 | FC8.2 | Analysis of hypothalamic metabolic circuits after normalization of body weight in mice that had been obese due to high fat diet intake |
| 10:20 | FC8.3 | Absence of central adrenal insufficiency in adults with Prader-Willi syndrome |
| 10:30 | FC8.4 | Peripheral and hypothalamic alterations in the insulin like growth factor IGF system in response to high fat diet induced weight gain |
| 10:40 | FC8.5 | LGR4-Wnt β-catenin signalling directs GnRH network development, with defects leading to self-limited delayed puberty |
| 10:50 | FC8.6 | Source and changes in serum level of kisspeptin in female rats at different developmental stages |
| 09:30-11:00 | | FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 9 - Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia)
Chair(s): Pratik Shah (London, United Kingdom) & Jacques Beltrand (Paris, France)
E2
|
| 09:30 | RFC9.1 | Targeted next-generation sequencing for congenital hypothyroidism with positive neonatal TSH screening results |
| 09:35 | RFC9.2 | Age-specific reference values for plasma FT4 and TSH concentrations in healthy, term neonates at day three to seven, and 13 to 15 of life |
| 09:40 | RFC9.3 | Neonatal screening for congenital hypothyroidism analysis of a large cohort of affected patients 1987 2017 and relationship with perfluoroalkylated substances PFAs in north eastern Italy |
| 09:45 | RFC9.4 | Correlation between genotype and phenotype characteristics in children with congenital hyperinsulinism (CHI) in a specialist centre |
| 09:50 | RFC9.5 | Spectrum of neuro-developmental disorders in children with congenital hyperinsulinism due to activating mutations in GLUD1 |
| 09:55 | RFC9.6 | Extra uterine growth restriction (EUGR) in very low birth weight infants: growth recovery and neurodevelopment by the corrected age of 2 years old |
| 10:00 | FC9.1 | Using CRISPR/Cas9 gene editing to study the molecular mechanisms of congenital hyperinsulinism (CHI) |
| 10:10 | FC9.2 | Heterozygous insulin receptor (INSR) mutation associated with neonatal hyperinsulinaemic hypoglycaemia and familial diabetes mellitus |
| 10:20 | FC9.3 | DNA methylation signatures in placenta and umbilical cord: association with maternal obesity |
| 10:30 | FC9.4 | Prenatal environment and genetic background influence urinary steroid excretion in monozygotic twins with intra-twin birth-weight differences |
| 10:40 | FC9.5 | Iodine status of pregnant women and their newborns in the UK – the MABY study |
| 10:50 | FC9.6 | [18F]F-DOPA-PET/MRI or /CT in children with congenital hyperinsulinism |
| 09:30-11:00 | | FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 10 - Sex differentiation, gonads and gynaecology or sex endocrinology
Chair(s): Ken McElreavey (Paris, France) & Anna Nordenström (Stockholm, Sweden)
F1
|
| 09:30 | RFC10.1 | Contemporary surgical approach in CAH 46XX – results from the I-DSD/I-CAH registries |
| 09:35 | RFC10.2 | Cryptorchid boys with abrogated mini-puberty display differentially expressed genes involved in sudden infant death syndrome |
| 09:40 | RFC10.3 | Level of uncertainty in diagnostic evaluation of boys with XY disorders of sex development (DSD) |
| 09:45 | RFC10.4 | qPCR screening for Xp21.2 copy number variations in patients with elusive aetiology of 46,XY DSD |
| 09:50 | RFC10.5 | Variants in NWD1 gene leading to different degrees of gonadal dysgenesis |
| 09:55 | RFC10.6 | A mutation in the nucleoporin-107 gene causes aberrant Dpp/BMP signaling and XX gonadal dysgenesis |
| 10:00 | FC10.1 | Investigating the roles of androgens in male reproductive development, maintenance and function by characterisation of androgen and cortisol deficient 11ß-hydroxylase mutant zebrafish lines |
| 10:10 | FC10.2 | The fruit fly, Drosophila melanogaster, as a model to elucidate human differences of sex development (DSD) |
| 10:20 | FC10.3 | Mutations in the DEAH-box RNA helicase DHX37 are a frequent cause of 46,XY gonadal dysgenesis and 46,XY testicular regression syndrome |
| 10:30 | FC10.4 | Loss-of-function and missense mutations in MYRF are a novel cause of autosomal dominant 46,XY Leydig cell hypoplasia and 46,XY gonadal dysgenesis |
| 10:40 | FC10.5 | Transcriptome analysis of novel Sertoli cell models to highlight potential genes involved in DSD mechanism of disease |
| 10:50 | FC10.6 | Evaluation of basal and GnRH stimulated AMH levels in central precocious puberty peripheral precocious puberty and premature thelarche |
| 09:30-11:00 | | ERN SESSION
Chair(s): Anita Hokken-Koelega (Rotterdam, The Netherlands) & Peter Clayton (Manchester, United Kingdom)
F2
|
| 09:30 | ERN1.1 | Progress in ENDO-ERN |
| 09:45 | ERN1.1 | The Lifelong management of Childhood Craniopharyngioma |
| 10:15 | ERN1.2 | ePAG Representitive |
| 10:30 | ERN1.3 | Thyroid Signalling Defects |
| 11:00-11:30 | | REFRESHMENT BREAK, POSTERS & EXHIBITION
Exhibition Area
|
| 11:30-12:00 | | ESPE AWARDS - Andrea Prader Prize
HALL A
Session head(s): Peter Clayton (Manchester, United Kingdom)
|
| 12:00-12:30 | | PLENARY 3
Chair(s): Nils Krone (Sheffield, United Kingdom) & Keiichi Ozono (Osaka, Japan)
Glucocorticoid rhythms, stress response and the brain from neonates to adults
HALL A
|
| PL3 | Glucocorticoid rhythms, stress response and the brain from neonates to adults |
| 12:30-13:00 | | ESPE AWARDS
HALL A
|
| | ESPE Hormone Research in Paediatrics Prizes - Supported by S. Karger AG |
| | IFCAH - ESPE Award - Supported by the International Fund Research on Congenital Adrenal Hyperplasia |
| | ESPE International Outstanding Clinician Award |
| | Outstanding Clinician Award |
| 13:00-14:30 | | LUNCH, POSTERS & EXHIBITION
Exhibition Area
|
| 13:15-14:15 | | Industry-Sponsored Satellite Symposia
|
| 14:00-16:00 | | Global Pediatric Endocrinology and Diabetes (GPED) - The Long Winding Road towards Sustainable Access to Affordable Insulin
Chair(s): Reiko Horikawa (Japan) & Ganesh Jevalikar (India)
F1
|
| 14:00 | | Introduction |
| 14:05 | | Why are we failing to address the issue of access to insulin in low- and middle- income countries? A global perspective |
| 14:35 | | Insulin access: from the model list of essential medicines to the patient: new WHO initiatives |
| 15:05 | | Access to insulin in China: barriers and opportunities |
| 15:35 | | Round table: how to be a leader on insulin access in your country? |
| 14:30-16:00 | | CONTROVERSY
Does obesity need tertiary care provision?
HALL A
Session head(s): Evangelia Charmandari (Athens, Greece)
|
| CON1.1 | PRO: Does obesity need tertiary care provision? |
| CON1.2 | CON: Does obesity need tertiary care provision? |
| 14:30-16:00 | | SYMPOSIUM 5
Chair(s): Andrew Dauber (Washington, USA) & Irène Netchine (Paris, France)
Impact of genomics on growth
E1
|
| S5.1 | Novel insights into genetic disorders of growth |
| S5.2 | SHOX: From Basic Research to Complex Models and Therapy |
| S5.3 | The role of KCNQ1in pituitary development |
| 14:30-16:00 | | SYMPOSIUM 6
Chair(s): Sabine Hannema (Leiden, The Netherlands) & Gary Butler (London, United Kingdom)
Endocrinology meets diversity: Transgender Youth
HALL B
|
| S6.1 | Impact of cross-gender hormone treatment on structural brain networks |
| S6.2 | Psychiatric comorbidities in Transgender Youth |
| S6.3 | Gynecological aspects and fertility issues in transgender adolescents |
| 14:30-16:00 | | SYMPOSIUM 7 - New Horizens in the Management in Adrenal Insufficiency
Chair(s): Christa Flück (Bern, Switzerland) & Walter Bonfig (Grieskirchen, Austria)
HALL C
|
| S7.1 | Novel interventions to treat adrenal insufficiency |
| S7.2 | Novel insights into the pathophysiology of adrenal insufficiency syndromes |
| S7.3 | Widening the horizon - Clinical relevance of steroid hormone pathways |
| 14:30-16:30 | | ESPE Nursing and Allied Health Working Group (PENS)
F2
Session head(s): Christine Derycke (Brussels, Belgium)
|
| 14:30 | WG8.1 | New topics in Turner Syndrome |
| 14:50 | | Discussion |
| 14:55 | WG8.2 | Care and Follow up of girls with Turner Syndrome in Northern Sweden |
| 15:15 | | Discussion |
| 15:20 | WG8.3 | What’s New in CAH? |
| 15:40 | | Discussion |
| 15:45 | WG8.4 | Gynaecologic nursing care for CAH |
| 16:05 | | Discussion |
| 16:10 | WG8.5 | Patient perspectives on CAH |
| 16:00-16:30 | | PLENARY 4
Chair(s): Anders Juul (Copenhagen, Denmark) & Luca Persani (Milan, Italy)
HPG -Nutrition and the hypothalamo-pituitary-gonadal axis
HALL A
|
| PL4 | HPG -Nutrition and the hypothalamo-pituitary-gonadal axis |
| 16:30-16:45 | | REFRESHMENT BREAK, POSTERS & EXHIBITION
Exhibition Area
|
| 16:45-18:15 | | Industry-Sponsored Satellite Symposia
|
| 17:00-18:00 | | NOVEL ADVANCES 1
Chair(s): Nicolas de Roux (Paris, France)
Stem cell reprogramming, IPS cells
HALL B
|
| NA1 | Single Cell technologies |
| 18:15-19:30 | | ESPE ANNUAL BUSINESS MEETING
F2
|
Saturday 21 September 2019 |
| 07:30-18:30 | | REGISTRATION
|
| 08:00-09:00 | | MEET THE EXPERT 2.2
The Interpretation of Abnormal Thyroid Function Tests in Children and Adolescents
E1
|
| MTE2.2 | The interpretation of abnormal thyroid function tests in children and adolescents |
| 08:00-09:00 | | MEET THE EXPERT 3.2
Clinical Practice Guidelines for the Care of Girls and Women with Turner Syndrome: Proceedings from the 2016 Cincinnati International Turner Syndrome Meeting
HALL B
|
| MTE3.2 | Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International |
| 08:00-09:00 | | MEET THE EXPERT 4.2
Klinefelter syndrome - when should testosterone be started
E2
|
| MTE4.2 | Klinefelter syndrome - when should testosterone be started |
| 08:00-09:00 | | MEET THE EXPERT 5.2
Managing endocrinopathies in McCune-Albright Syndrome
HALL C
|
| MTE5.2 | Managing endocrinopathies in McCune-Albright Syndrome |
| 08:00-09:00 | | YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 3
HALL A
|
| 08:00 | YB3.1 | Pituitary and Neuroendocrinology |
| 08:12 | YB3.2 | Puberty |
| 08:24 | YB3.3 | Thyroid |
| 08:36 | YB3.4 | Type 1 Diabetes |
| 08:48 | YB3.5 | The Year in Science & Medicine |
| 09:00-10:30 | | HOW DO I...
Chair(s): Marco Cappa (Rome, Italy)
HOW DO I...SESSION 2
HALL A
|
| 09:00 | HDI2.1 | How do I…. Manage micropenis in a child? |
| 09:30 | HDI2.2 | How Do I... Diagnosing growth hormone resistance? |
| 10:00 | HDI2.3 | How Do I... Manage of an asymptomatic child with T1D and transglutaminase positivity? |
| 09:00-10:30 | | FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 11 - Pituitary, neuroendocrinology and metabolism Session 2
Chair(s): Gerhard Binder (Tübingen, Germany) & Katharina Main (Copenhagen, Denmark)
HALL B
|
| 09:00 | RFC11.1 | National United Kingdom evidence- and consensus-based guidelines for the investigation, treatment and long-term follow-up of paediatric craniopharyngioma |
| 09:05 | RFC11.2 | Prevalence and predicting factors of endocrine dysfunction in children with NF1 and optic gliomas |
| 09:10 | RFC11.3 | Polycystic ovarian syndrome in adolescents: utilising discovery proteomics and the search to identify novel non-invasive biomarkers |
| 09:15 | RFC11.4 | Increased adrenal and testicular androgen concentrations before puberty and in early puberty correlate to adult height outcomes in males with Silver–Russell syndrome |
| 09:20 | RFC11.5 | IGF-1 serum concentrations and growth in children with congenital leptin deficiency (CLD) before and after replacement therapy with metreleptin |
| 09:25 | RFC11.6 | Final height reduction in transgender adolescent girls: a case series |
| 09:30 | FC11.1 | Phenotypic characterization of a large pediatric cohort of patients with genetic forms of congenital hypopituitarism |
| 09:40 | FC11.2 | A novel minor spliceosome defect associated with growth hormone deficiency GHD and primary ovarian insufficiency POI |
| 09:50 | FC11.3 | A novel genetic aetiology for familial neonatal central diabetes insipidus |
| 10:00 | FC11.4 | Whole exome sequencing in a familial case of adamantinomatous craniopharyngioma revealed two hits affecting Wnt-signaling pathway |
| 10:10 | FC11.5 | Survival, endocrine disorders and quality of life in 135 children with craniopharyngioma after surgical or combined treatment |
| 10:20 | FC11.6 | Pubertal timing in parents is associated with timing of pubertal milestones in offspring of concordant sex – but only inconsistently with milestones in offspring of discordant sex |
| 09:00-10:30 | | FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 12 - Growth and syndromes (to include Turner syndrome)
Chair(s): Sandro Loche (Cagliari, Italy) & Helen Storr (London, United Kingdom)
HALL C
|
| 09:00 | RFC12.1 | Karyotyping of oocytes, granulosa cells and stromal cells in the ovarian tissue from patients with Turner syndrome: a pilot study |
| 09:05 | RFC12.2 | Treatment with growth hormone increases Klotho concentration in patients with Turner syndrome |
| 09:10 | RFC12.3 | Imprinting defects and copy number variations in short children born small for gestational age |
| 09:15 | RFC12.4 | NIPBL is required for postnatal growth and neural development |
| 09:20 | RFC12.5 | Cognitive and neuroradiological assessments in Silver Russell patients |
| 09:25 | RFC12.6 | Exploring the usefulness of a new type of pubertal height reference based on growth aligned or onset of pubertal growth |
| 09:30 | FC12.1 | Increasing knowledge in IGF1R defects: lessons from 20 new patients. |
| 09:40 | FC12.2 | NPR2 gene mutations were found in 5.4% children with familial short stature |
| 09:50 | FC12.3 | Growth hormone treatment in adults with Prader–Willi syndrome has sustained positive effects on body composition |
| 10:00 | FC12.4 | Integration of transcriptomic and epigenomic data in childhood identifies a subset of individuals born small for gestational age (SGA) with “catch-up” growth who become pre-hypertensive in early adulthood |
| 10:10 | FC12.5 | Integrated analysis of baseline blood transcriptome and genome identifies clusters of Turner syndrome patients with different responses to recombinant human growth hormone |
| 10:20 | FC12.6 | An integrated systems biology analysis of the genome, epigenome and transcriptome identifies a distinct pattern of hypermethylation associated with low childhood growth |
| 09:00-10:30 | | FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 13 - Adrenals and HP axis
Chair(s): Stefan Wudy (Gießen, Germany) & Angela Huebner (Dresden, Germany)
E1
|
| 09:00 | RFC13.1 | Children and adolescents in the United States with congenital adrenal hyperplasia are not at increased risk for attention-deficit/hyperactivity disorder |
| 09:05 | RFC13.2 | Development of novel non-invasive strategies for monitoring of treatment control in patients with congenital adrenal hyperplasia |
| 09:10 | RFC13.3 | Establishment of reference intervals for hair cortisol in healthy children aged 0-18 years using mass spectrometric analysis |
| 09:15 | RFC13.4 | Loss-of-function NNT mutations impair antioxidants mechanisms and decreases cortisol secretion in patients with familial glucocorticoid deficiency |
| 09:20 | RFC13.5 | Genetics of familial glucocorticoid deficiency over the decades: phenotypic variability and associated features |
| 09:25 | RFC13.6 | Inhibitory effects of curcuminoids on the enzymes from the steroidogenic pathway |
| 09:30 | FC13.1 | Peptide MC2R antagonists as a new potential therapeutic approach for congenital adrenal hyperplasia |
| 09:40 | FC13.2 | Sexual dimorphism in cortisol production and metabolism throughout pubertal development: a longitudinal study |
| 09:50 | FC13.3 | YAP1-HIPPO pathway as a novel prognostic marker and therapeutic target for pediatric patients with adrenocortical tumors (ACT) |
| 10:00 | FC13.4 | Biphasic glucocorticoid rhythm in one-month old infants: reflection of a developing HPA-axis? |
| 10:10 | FC13.5 | SGPL1 deficiency leads to downregulation of key enzymes within the steroidogenic pathway |
| 10:20 | FC13.6 | Insights into the role of cortisol in the formation of the Clock/Bmal1 complex and its interaction with dsDNA, via molecular dynamics simulations |
| 09:00-10:30 | | FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 14 - GH and IGF1
Chair(s): Ivo Arnhold (Sao Paulo, Brazil) & Joachim Woelfle (Erlangen, Germany)
E2
|
| 09:00 | RFC14.1 | Papp-a2 deficiency results in sex-dependent modifications in hypothalamic regulation of energy homeostasis |
| 09:05 | RFC14.2 | Deciphering genetic aetiology among children born small-for-gestational-age with persistent short stature (SGA-SS): phenotypic characteristics at diagnosis in a large single-centre cohort |
| 09:10 | RFC14.3 | MicroRNAs change and target key regulatory genes involved in longitudinal growth in patients with idiopathic isolated growth hormone deficiency (IGHD) on growth hormone (GH) treatment |
| 09:15 | RFC14.4 | GHR transcript heterogeneity may explain the phenotypic variability in patients with homozygous GHR pseudoexon (6Ψ) mutation |
| 09:20 | RFC14.5 | Bioactive IGF-I concentration compared to total IGF-I concentration before and after 1 year of high-dose growth hormone in short children born small for gestational age – North European SGA Study (NESGAS) |
| 09:25 | RFC14.6 | Growth hormone deficiency (GHD): assessing burden of disease in children and adolescents: the growth hormone deficiency – child impact measure (GHD-CIM) |
| 09:30 | FC14.1 | Inhibition of IGF1R by IGF1R/IR inhibitor OSI906 as a targeted therapy for glioblastoma: in vitro & in vivo studies |
| 09:40 | FC14.2 | Pubertal onset in 1572 girls with short, normal and tall stature: associations to height, serum IGF-I and PAPP-A2 genotypes |
| 09:50 | FC14.3 | Papp-a2 deficiency induces sex-specific changes in hydroxyapatite-(CaOH) crystallinity and the effects of IGF-1 on bone composition in adult mice |
| 10:00 | FC14.4 | Once-weekly TransCon hGH vs. Daily hGH in pediatric growth hormone deficiency: the phase 3 heiGHt trial |
| 10:10 | FC14.5 | Once-weekly somapacitan vs daily growth hormone (Norditropin®) in childhood growth hormone deficiency: One-year results from a randomised phase 2 trial |
| 10:20 | FC14.6 | Effects of 8 years of growth hormone treatment on cognition in children with Prader–Willi syndrome |
| 09:00-10:30 | | FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 15 - Late Breaking Session
Chair(s): Lou Metherell (London, UK) & Yves Le-Bouc (Paris, France)
F1
|
| 09:00 | RFC15.1 | Preclinical studies of acrodysostosis gene aav therapy in a knock in r368 x prkar1 a mouse model |
| 09:05 | RFC15.2 | BMP4 mutations as a novel cause of normosmic hypogonadotropic hypogonadism |
| 09:10 | RFC15.3 | Metformin treatment affects ACTH receptor activation and downstream signaling: a potential treatment for ACTH excess disorders and management of hyperandrogenic states |
| 09:15 | RFC15.4 | Clinical and genetic characterization of 148 patients with persistent or transient congenital hyperinsulinism: a population-based study in Finns |
| 09:20 | RFC15.5 | De novo missense mutation in SP7 in a patient with cranial hyperostosis, long bone fragility, and increased osteoblast number |
| 09:25 | RFC15.6 | Absence of puberty and estrogen resistance by estrogen alpha receptor inactivation in two sisters: a mutation for variable phenotypic severity |
| 09:30 | FC15.1 | DLG2 mutations in patients with delayed or absent puberty |
| 09:40 | FC15.2 | HDAC4 mutations cause diabetes and induce β-cell FoxO1 nuclear exclusion |
| 09:50 | FC15.3 | The P450 side-chain cleavage isozyme cyp11a2 facilitates interrenal and gonadal steroid hormone biosynthesis in developing and adult zebrafish |
| 10:00 | FC15.4 | Defects in the GnRH neuroendocrine network affect the timing of puberty |
| 10:10 | FC15.5 | Effects of Bifidobacterium animalis subsp. lactis on children with Prader–Willi syndrome: a randomized, double-blind, placebo-controlled, crossover trial |
| 10:20 | FC15.6 | Leptin influences the down-regulation of UCP-1 expression in brown adipose tissue during negative energy balance |
| 10:30-11:00 | | REFRESHMENT BREAK, POSTERS & EXHIBITION
Exhibition Area
|
| 11:00-11:30 | | PLENARY 5
Chair(s): Stefan Riedl (Vienna, Austria) & Faisal Ahmed (Glasgow, United Kingdom)
How to reduce waste and increase value in translational biomedical research
HALL A
|
| PL5 | How to reduce waste and increase value in translational biomedical research |
| 11:30-12:00 | | ESPE AWARDS
ESPE Research Award
HALL A
Session head(s): Agnès Linglart (Paris, France)
|
| 12:00-12:30 | | PLENARY 6
Chair(s): Mehul T. Dattani (London, United Kingdom) & Rasa Verkauskiene (Kaunas, Lithuania)
Pituitary Gigantism - an update
HALL A
|
| PL6 | Pituitary Gigantism - an update |
| 12:30-14:00 | | LUNCH, POSTERS & EXHIBITION
Exhibition Area
|
| 12:45-13:45 | | Industry Sponsored Satellite Symposia
|
| 14:00-15:00 | | YOUNG INVESTIGATORS SESSION
F1
Session head(s): Faisal Ahmed (Glasgow, United Kingdom)
|
| YI1.1 | In search for novel monitoring tools to detect chronic over- or under-treatment in children with CAH |
| YI1.2 | The role of the gut microbiome in metabolism |
| | ESPE Young Investigator Awards |
| 14:00-15:00 | | MEET THE EXPERT 6.2
Management of Diabetic Ketoacidosis
HALL B
|
| MTE6.2 | Management of Diabetic Ketoacidosis |
| 14:00-15:00 | | MEET THE EXPERT 7.2
Management of Graves disease
E2
|
| MTE7.2 | Management of Graves disease |
| 14:00-15:00 | | MEET THE EXPERT 8.2
Management of neonatal hypoglycaemia
HALL C
|
| MTE8.2 | Management of neonatal hypoglycaemia |
| 14:00-15:00 | | NOVEL ADVANCES 2
Genetic imprinting analysis in clinical practice
E1
|
| NA2 | Genetic imprinting analysis in clinical practice |
| 15:00-15:30 | | REFRESHMENT BREAK, POSTERS & EXHIBITION
Exhibition Area
|
| 15:30-17:00 | | SYMPOSIUM 8
Chair(s): Elke Froehlich-Reiterer (Graz, Austria) & Loredana Marcovecchio (Cambridge, United Kingdom)
Autoimmunity: From diagnosis to treatment
E1
|
| 15:30 | S8.1 | New autoantibodies in endocrine autoimmunity development: Lessons from APECED |
| 16:00 | S8.2 | Novel monogenic forms of autoimmune diabetes |
| 16:30 | S8.3 | Bone marrow transplant for genetically determined autoimmunity |
| 15:30-17:00 | | SYMPOSIUM 9
Chair(s): Stepanka Pruhova (Prague, Czech Republic) & Francesco Chiarelli (Chieti, Italy)
Heterogeneity of paediatric diabetes
HALL B
|
| S9.1 | Diversity in monogenic diabetes management and prognosis |
| S9.2 | Diagnostic and therapeutic implications of double diabetes |
| S9.3 | Obesity and T2 diabetes: How to find a population at risk |
| 15:30-17:00 | | SYMPOSIUM 10
Chair(s): Cheri Deal (Montreal, Canada)
Brain development and sex: Is it chromosomes or hormones?
E2
|
| S10.1 | Multifaceted origins of sex differences in the brain |
| S10.2 | The pubertal brain |
| S10.3 | How hormones impact on emotion and cognition --- new insights from Magnetic resonance imaging |
| 15:30-17:00 | | SYMPOSIUM 11
Chair(s): Leo Dunkel (London, United Kingdom) & Mohamad Maghnie (Genoa, Italy)
Recent advances in our understanding of Hypogonadotrophic hypogonadism
HALL C
|
| S11.1 | Novel insights into the molecular basis of hypogonadotrophic hypogonadism |
| S11.2 | Novel insights into the regulation of reproduction from 3D imaging of the GnRH and kisspeptin neuronal populations |
| S11.3 | Novel insights into the role of semaphorin signalling in GnRH neuron development and failure |
| 17:00-17:30 | | ESPE AWARDS
HALL A
|
| | ESPE International Award |
| | ESPE President Poster Awards |
| 17:30-18:00 | | PLENARY 7
Chair(s): Asma Deeb (Abu Dhabi, UAE) & Tadej Battelino (Ljubljana, Slovenia)
Novel advances in artificial pancreas development
HALL A
|
| PL7 | Novel advances in artificial pancreas development |
| 18:00-18:15 | | ESPE 2019 CLOSING CEREMONY
HALL A
|
| 19:00-00:00 | | THE ESPE EVENING
THE CITY HALL
|